title: [Life-threatening serotonin syndrome following a single dose of a serotonin reuptake inhibitor during maintenance therapy with a monoamine oxidase inhibitor].
abstract: A 72-year-old man presented to the emergency clinic with motor restlessness and diminished consciousness 24 hours after he had mistakenly been given venlafaxine. He was referred from the psychiatric clinic where he was treated with tranylcypromine. Shortly after arrival, a severe serotonin syndrome developed with generalised myoclonic seizures, hyperreflexia, hypertonia, a rapid increase in temperature to 40.9 degrees C, hypertension, tachycardia, respiratory insufficiency, hyperkalaemia and metabolic acidosis. The patient was treated with the sedative propofol and the muscle relaxant rocuronium, followed by intubation and artificial respiration. He was cooled on a cooling mattress. Twenty-four hours later the airway tube could be removed and after 48 hours he was returned to the psychiatric ward in good condition. Tranylcypromine is a monoamine oxidase inhibitor and venlafaxine is a serotonin and noradrenaline reuptake inhibitor. When two serotoninergic agents are combined, the serotonin syndrome may develop, and this may be life-threatening. The treatment of this syndrome with propofol and rocuronium can be given quickly and safely in practically every hospital.
authors.affiliation: Universitair Medisch Centrum St Radboud, Nijmegen. anke.marije.zonneveld@znb.nl
authors.forename: A M
authors.initials: AM
authors.lastname: Zonneveld
authors.forename: M
authors.initials: M
authors.lastname: Hagenaars
authors.forename: N C
authors.initials: NC
authors.lastname: Voermans
authors.forename: H P M M
authors.initials: HP
authors.lastname: Gelissen
authors.forename: J A H R
authors.initials: JA
authors.lastname: Claassen
mesh_terms: D000368:Aged; D000465:Algorithms; D000928:Antidepressive Agents / Q000009:adverse effects; D003951:Diagnostic Errors; D004347:Drug Interactions; D062787:Drug Overdose / Q000150:complications; D006801:Humans; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects; D020230:Serotonin Syndrome / Q000139:chemically induced / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects
chemical_list: D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors